152 related articles for article (PubMed ID: 33161023)
1. p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer.
Bae HJ; Kang SK; Kwon WS; Jeong I; Park S; Kim TS; Kim KH; Kim H; Jeong HC; Chung HC; Rha SY
Biochem Pharmacol; 2021 Jan; 183():114320. PubMed ID: 33161023
[TBL] [Abstract][Full Text] [Related]
2. Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
Dowless M; Lowery CD; Shackleford T; Renschler M; Stephens J; Flack R; Blosser W; Gupta S; Stewart J; Webster Y; Dempsey J; VanWye AB; Ebert P; Iversen P; Olsen JB; Gong X; Buchanan S; Houghton P; Stancato L
Clin Cancer Res; 2018 Dec; 24(23):6028-6039. PubMed ID: 30131386
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.
O'Brien N; Conklin D; Beckmann R; Luo T; Chau K; Thomas J; Mc Nulty A; Marchal C; Kalous O; von Euw E; Hurvitz S; Mockbee C; Slamon DJ
Mol Cancer Ther; 2018 May; 17(5):897-907. PubMed ID: 29483214
[TBL] [Abstract][Full Text] [Related]
4. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition.
Dhir T; Schultz CW; Jain A; Brown SZ; Haber A; Goetz A; Xi C; Su GH; Xu L; Posey J; Jiang W; Yeo CJ; Golan T; Pishvaian MJ; Brody JR
Mol Cancer Res; 2019 Oct; 17(10):2029-2041. PubMed ID: 31383722
[TBL] [Abstract][Full Text] [Related]
5. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
6. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780
[TBL] [Abstract][Full Text] [Related]
8. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
9. REC8 functions as a tumor suppressor and is epigenetically downregulated in gastric cancer, especially in EBV-positive subtype.
Yu J; Liang Q; Wang J; Wang K; Gao J; Zhang J; Zeng Y; Chiu PW; Ng EK; Sung JJ
Oncogene; 2017 Jan; 36(2):182-193. PubMed ID: 27212034
[TBL] [Abstract][Full Text] [Related]
10. The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
Schaer DA; Beckmann RP; Dempsey JA; Huber L; Forest A; Amaladas N; Li Y; Wang YC; Rasmussen ER; Chin D; Capen A; Carpenito C; Staschke KA; Chung LA; Litchfield LM; Merzoug FF; Gong X; Iversen PW; Buchanan S; de Dios A; Novosiadly RD; Kalos M
Cell Rep; 2018 Mar; 22(11):2978-2994. PubMed ID: 29539425
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Eukaryotic Initiating Factor eIF4E Overcomes Abemaciclib Resistance in Gastric Cancer.
Zha HL; Chen W; Shi W; Liao YY
Curr Med Sci; 2023 Oct; 43(5):927-934. PubMed ID: 37752406
[TBL] [Abstract][Full Text] [Related]
12. P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib.
Li P; Zhang X; Gu L; Zhou J; Deng D
PLoS One; 2019; 14(10):e0223084. PubMed ID: 31652270
[TBL] [Abstract][Full Text] [Related]
13. Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas.
Tanaka Y; Momose S; Tabayashi T; Sawada K; Yamashita T; Higashi M; Sagawa M; Tokuhira M; Rosenwald A; Kizaki M; Tamaru JI
Cancer Sci; 2020 Feb; 111(2):749-759. PubMed ID: 31849147
[TBL] [Abstract][Full Text] [Related]
14. Reduced expression and promoter methylation of p16 gene in Epstein-Barr virus-associated gastric carcinoma.
Osawa T; Chong JM; Sudo M; Sakuma K; Uozaki H; Shibahara J; Nagai H; Funata N; Fukayama M
Jpn J Cancer Res; 2002 Nov; 93(11):1195-200. PubMed ID: 12460459
[TBL] [Abstract][Full Text] [Related]
15. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Palumbo A; Lau G; Saraceni M
Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
[TBL] [Abstract][Full Text] [Related]
16. Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer
Naz S; Sowers A; Choudhuri R; Wissler M; Gamson J; Mathias A; Cook JA; Mitchell JB
Clin Cancer Res; 2018 Aug; 24(16):3994-4005. PubMed ID: 29716919
[No Abstract] [Full Text] [Related]
17. Abemaciclib for the treatment of breast cancer.
Kotake T; Toi M
Expert Opin Pharmacother; 2018 Apr; 19(5):517-524. PubMed ID: 29522364
[TBL] [Abstract][Full Text] [Related]
18. Methylation of drug resistance-related genes in chemotherapy-sensitive Epstein-Barr virus-associated gastric cancer.
Ohmura H; Ito M; Uchino K; Okada C; Tanishima S; Yamada Y; Momosaki S; Komoda M; Kuwayama M; Yamaguchi K; Okumura Y; Nakano M; Tsuchihashi K; Isobe T; Ariyama H; Kusaba H; Oda Y; Akashi K; Baba E
FEBS Open Bio; 2020 Jan; 10(1):147-157. PubMed ID: 31736281
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
20. Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show chromosomal instability, but MSI tumors do exist.
Tsuruta S; Ohishi Y; Fujiwara M; Ihara E; Ogawa Y; Oki E; Nakamura M; Oda Y
Hum Pathol; 2019 Jun; 88():27-38. PubMed ID: 30946937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
